{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T15:21:20Z","timestamp":1783005680372,"version":"3.54.5"},"reference-count":76,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.ejmech.2023.115180","type":"journal-article","created":{"date-parts":[[2023,2,3]],"date-time":"2023-02-03T01:56:44Z","timestamp":1675389404000},"page":"115180","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":55,"special_numbering":"C","title":["4-(5-Amino-pyrazol-1-yl)benzenesulfonamide derivatives as novel multi-target anti-inflammatory agents endowed with inhibitory activity against COX-2, 5-LOX and carbonic anhydrase: Design, synthesis, and biological assessments"],"prefix":"10.1016","volume":"250","author":[{"given":"Mahmoud A.","family":"Ragab","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6996-4017","authenticated-orcid":false,"given":"Wagdy M.","family":"Eldehna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio","family":"Nocentini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Bonardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hazem E.","family":"Okda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bahaa","family":"Elgendy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarek S.","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad M.","family":"Abd-Alhaseeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Gratteri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudiu T.","family":"Supuran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed A.","family":"Al-Karmalawy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Elagawany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ejmech.2023.115180_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/1875041901205010001","article-title":"Definition of inflammation, causes of inflammation and possible anti-inflammatory strategies","volume":"5","author":"Stankov","year":"2012","journal-title":"Open Inflamm. J."},{"key":"10.1016\/j.ejmech.2023.115180_bib2a","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3389\/fneur.2017.00251","article-title":"Highly selective cyclooxygenase-1 inhibitors P6 and mofezolac counteract inflammatory state both in vitro and in vivo models of neuroinflammation","volume":"8","author":"Calvello","year":"2017","journal-title":"Front. Neurol."},{"issue":"1","key":"10.1016\/j.ejmech.2023.115180_bib2b","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.phrs.2011.09.009","article-title":"Paola Vitale, Paola Malerba, and Antonio Scilimati. \"Novel selective COX-1 inhibitors suppress neuroinflammatory mediators in LPS-stimulated N13 microglial cells","volume":"65","author":"Calvello","year":"2012","journal-title":"Pharmacol. Res."},{"issue":"6","key":"10.1016\/j.ejmech.2023.115180_bib3a","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/nchembio.375","article-title":"COX-2's new role in inflammation","volume":"6","author":"Chen","year":"2010","journal-title":"Nat. Chem. Biol."},{"issue":"1\u20132","key":"10.1016\/j.ejmech.2023.115180_bib3b","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1159\/000369826","article-title":"Selective cyclooxygenase-1 inhibition by P6 and gastrotoxicity: preliminary investigation","volume":"95","author":"Perrone","year":"2015","journal-title":"Pharmacology"},{"issue":"3","key":"10.1016\/j.ejmech.2023.115180_bib4","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/nrd1034","article-title":"The development of COX2 inhibitors","volume":"2","author":"Flower","year":"2003","journal-title":"Nat. Rev. Drug Discov."},{"issue":"34","key":"10.1016\/j.ejmech.2023.115180_bib5","doi-asserted-by":"crossref","first-page":"23679","DOI":"10.1074\/jbc.274.34.23679","article-title":"Lipoxygenases: occurrence, functions, catalysis, and acquisition of substrate","volume":"274","author":"Brash","year":"1999","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2023.115180_bib6","doi-asserted-by":"crossref","unstructured":"Meshram, Minakshi A., Utkarsha O. Bhise, Priyanka N. Makhal, and Venkata Rao Kaki. \"Synthetically-tailored and nature-derived dual COX-2\/5-LOX inhibitors: structural aspects and SAR.\" Eur. J. Med. Chem. 225 (2021): 113804.","DOI":"10.1016\/j.ejmech.2021.113804"},{"key":"10.1016\/j.ejmech.2023.115180_bib7","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.ejps.2018.06.003","article-title":"Safer anti-inflammatory therapy through dual COX-2\/5-LOX inhibitors: a structure-based approach","volume":"121","author":"Manju","year":"2018","journal-title":"Eur. J. Pharmaceut. Sci."},{"issue":"12","key":"10.1016\/j.ejmech.2023.115180_bib8","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1016\/j.drudis.2014.08.006","article-title":"Multi-target approach for natural products in inflammation","volume":"19","author":"Koeberle","year":"2014","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2023.115180_bib9","first-page":"99","article-title":"Significance of the hydrogen ion concentration in synovial fluid in rheumatoid arthritis","volume":"3","author":"Farr","year":"1985","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.ejmech.2023.115180_bib10","doi-asserted-by":"crossref","first-page":"475","DOI":"10.3389\/fimmu.2018.00475","article-title":"The acid\u2013base balance and gender in Inflammation: a mini-review","volume":"9","author":"Casimir","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejmech.2023.115180_bib11","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.bbadis.2015.10.017","article-title":"Acidosis differently modulates the inflammatory program in monocytes and macrophages","volume":"1","author":"Riemann","year":"2016","journal-title":"Biochim. Biophys. Acta, Mol. Basis Dis."},{"key":"10.1016\/j.ejmech.2023.115180_bib12","first-page":"2018","article-title":"Unravelling the interplay between extracellular acidosis and immune cells","author":"Erra D\u00edaz","year":"2018","journal-title":"Mediat. Inflamm."},{"issue":"3","key":"10.1016\/j.ejmech.2023.115180_bib13","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/0304-3940(96)12576-3","article-title":"Pain due to tissue acidosis: a mechanism for inflammatory and ischemic myalgia?","volume":"208","author":"Issberner","year":"1996","journal-title":"Neurosci. Lett."},{"issue":"2","key":"10.1016\/j.ejmech.2023.115180_bib14","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/nrd2467","article-title":"Carbonic anhydrases: novel therapeutic applications for inhibitors and activators","volume":"7","author":"Supuran","year":"2008","journal-title":"Nat. Rev. Drug Discov."},{"issue":"8","key":"10.1016\/j.ejmech.2023.115180_bib15","doi-asserted-by":"crossref","first-page":"4421","DOI":"10.1021\/cr200176r","article-title":"Multiple binding modes of inhibitors to carbonic anhydrases: how to design specific drugs targeting 15 different isoforms?","volume":"112","author":"Alterio","year":"2012","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ejmech.2023.115180_bib16","doi-asserted-by":"crossref","first-page":"412","DOI":"10.3390\/metabo10100412","article-title":"Carbonic anhydrase inhibitors targeting metabolism and tumor microenvironment","volume":"10","author":"Angeli","year":"2020","journal-title":"Metabolites"},{"issue":"1","key":"10.1016\/j.ejmech.2023.115180_bib17","first-page":"1","article-title":"Increased expression of carbonic anhydrase I in the synovium of patients with ankylosing spondylitis","volume":"11","author":"Chang","year":"2010","journal-title":"BMC Muscoskel. Disord."},{"issue":"1","key":"10.1016\/j.ejmech.2023.115180_bib18","first-page":"1","article-title":"Transgenic mice over-expressing carbonic anhydrase I showed aggravated joint inflammation and tissue destruction","volume":"13","author":"Zheng","year":"2012","journal-title":"BMC Muscoskel. Disord."},{"key":"10.1016\/j.ejmech.2023.115180_bib19","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/354594","article-title":"Carbonic anhydrases III and IV autoantibodies in rheumatoid arthritis, systemic lupus erythematosus, diabetes, hypertensive renal disease, and heart failure","volume":"2012","author":"Liu","year":"2012","journal-title":"Clin. Dev. Immunol."},{"issue":"sup4","key":"10.1016\/j.ejmech.2023.115180_bib20","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1080\/14756366.2016.1217857","article-title":"Overexpression of the transmembrane carbonic anhydrase isoforms IX and XII in the inflamed synovium","volume":"31","author":"Margheri","year":"2016","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115180_bib21","doi-asserted-by":"crossref","unstructured":"Peerzada, Mudasir Nabi, Ernest Hamel, Ruoli Bai, Claudiu T. Supuran, and Amir Azam. \"Deciphering the key heterocyclic scaffolds in targeting microtubules, kinases and carbonic anhydrases for cancer drug development.\" Pharmacol. Therapeut. 225 (2021): 107860.","DOI":"10.1016\/j.pharmthera.2021.107860"},{"key":"10.1016\/j.ejmech.2023.115180_bib22","doi-asserted-by":"crossref","unstructured":"Elbadawi, Mostafa M., Wagdy M. Eldehna, Alessio Nocentini, Warda R. Somaa, Sara T. Al-Rashood, Eslam B. Elkaeed, Mahmoud A. El Hassab, Hatem A. Abdel-Aziz, Claudiu T. Supuran, and Mohamed Fares. \"Development of 4-((3-oxo-3-phenylpropyl) amino) benzenesulfonamide derivatives utilizing tail\/dual-tail approaches as novel carbonic anhydrase inhibitors.\" Eur. J. Med. Chem. 238 (2022): 114412.","DOI":"10.1016\/j.ejmech.2022.114412"},{"issue":"1","key":"10.1016\/j.ejmech.2023.115180_bib23","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1080\/14756366.2022.2124409","article-title":"Design and synthesis of benzothiazole-based SLC-0111 analogues as new inhibitors for the cancer-associated carbonic anhydrase isoforms IX and XII","volume":"37","author":"Al-Warhi","year":"2022","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115180_bib24","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.ejmech.2018.10.068","article-title":"Enhancement of the tail hydrophobic interactions within the carbonic anhydrase IX active site via structural extension: design and synthesis of novel N-substituted isatins-SLC-0111 hybrids as carbonic anhydrase inhibitors and antitumor agents","volume":"162","author":"Eldehna","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115180_bib25","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1021\/jm030912m","article-title":"Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: new pharmacological opportunities due to related binding site recognition","volume":"47","author":"Weber","year":"2004","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115180_bib26","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.bmcl.2005.09.040","article-title":"Carbonic anhydrase inhibitors: valdecoxib binds to a different active site region of the human isoform II as compared to the structurally related cyclooxygenase II \u2018selective\u2019 inhibitor celecoxib","volume":"16","author":"Fiore","year":"2006","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"1","key":"10.1016\/j.ejmech.2023.115180_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbrc.2016.07.114","article-title":"Structural insight into the inhibition of carbonic anhydrase by the COX-2-selective inhibitor polmacoxib (CG100649)","volume":"478","author":"Kim","year":"2016","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"6","key":"10.1016\/j.ejmech.2023.115180_bib28","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/j.bmc.2012.10.029","article-title":"New selective carbonic anhydrase IX inhibitors: synthesis and pharmacological evaluation of diarylpyrazole-benzenesulfonamides","volume":"21","author":"Rogez-Florent","year":"2013","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115180_bib29","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ejmech.2014.09.059","article-title":"Novel sulfonamides bearing pyrrole and pyrrolopyrimidine moieties as carbonic anhydrase inhibitors: synthesis, cytotoxic activity and molecular modeling","volume":"87","author":"Ghorab","year":"2014","journal-title":"Eur. J. Med. Chem."},{"issue":"10","key":"10.1016\/j.ejmech.2023.115180_bib30","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/nrclinonc.2015.105","article-title":"Inflammation and cancer: advances and new agents","volume":"12","author":"Crusz","year":"2015","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"6917","key":"10.1016\/j.ejmech.2023.115180_bib31","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/nature01322","article-title":"Inflammation and cancer","volume":"420","author":"Coussens","year":"2002","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.ejmech.2023.115180_bib32","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1080\/13543776.2019.1623880","article-title":"Selective COX-2 inhibitors as anticancer agents: a patent review (2014-2018)","volume":"29","author":"Rabbani","year":"2019","journal-title":"Expert Opin. Ther. Pat."},{"issue":"13","key":"10.1016\/j.ejmech.2023.115180_bib33","doi-asserted-by":"crossref","DOI":"10.3748\/wjg.v10.i13.1971","article-title":"Anti-cancer effects of COX-2 inhibitors and their correlation with angiogenesis and invasion in gastric cancer","volume":"10","author":"Fu","year":"2004","journal-title":"World J. Gastroenterol.: WJG"},{"issue":"12","key":"10.1016\/j.ejmech.2023.115180_bib34","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1080\/13543784.2021.2014813","article-title":"Carbonic anhydrase inhibitors: an update on experimental agents for the treatment and imaging of hypoxic tumors","volume":"30","author":"Supuran","year":"2021","journal-title":"Expet Opin. Invest. Drugs"},{"issue":"6","key":"10.1016\/j.ejmech.2023.115180_bib35","doi-asserted-by":"crossref","first-page":"668","DOI":"10.3390\/ph15060668","article-title":"Fluorochrome selection for imaging intraoperative ovarian cancer probes","volume":"15","author":"Perrone","year":"2022","journal-title":"Pharmaceuticals"},{"issue":"9","key":"10.1016\/j.ejmech.2023.115180_bib36","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1093\/abbs\/gmt064","article-title":"5-lipoxygenase antagonist therapy: a new approach towards targeted cancer chemotherapy","volume":"45","author":"Bishayee","year":"2013","journal-title":"Acta Biochim. Biophys. Sin."},{"issue":"9\u201310","key":"10.1016\/j.ejmech.2023.115180_bib37","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.drudis.2013.01.008","article-title":"Shifting from the single to the multitarget paradigm in drug discovery","volume":"18","author":"Medina-Franco","year":"2013","journal-title":"Drug Discov. Today"},{"issue":"1","key":"10.1016\/j.ejmech.2023.115180_bib38","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1080\/14756366.2021.1945049","article-title":"Multitargeting approaches involving carbonic anhydrase inhibitors: hybrid drugs against a variety of disorders","volume":"36","author":"Supuran","year":"2021","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115180_bib39","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3389\/fchem.2019.00071","article-title":"Multi-target-directed ligands (MTDL) as challenging research tools in drug discovery: from design to pharmacological evaluation","volume":"7","author":"Alcaro","year":"2019","journal-title":"Front. Chem."},{"issue":"8","key":"10.1016\/j.ejmech.2023.115180_bib40","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/ardp.19793120810","article-title":"Pyrazoles and pyrazolo[3,4\u2010d]pyrimidines as biologically active agents, II","volume":"312","author":"Ram","year":"1979","journal-title":"Arch. Pharm. (Weinheim)"},{"issue":"4","key":"10.1016\/j.ejmech.2023.115180_bib41","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/ardp.200800178","article-title":"Synthesis and biological evaluation of novel pyrazoles and pyrazolo[3,4-d]pyrimidines incorporating a benzenesulfonamide moiety","volume":"342","author":"Ashour","year":"2009","journal-title":"Arch. Pharm. (Weinheim)"},{"key":"10.1016\/j.ejmech.2023.115180_bib42","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.ejmech.2015.09.021","article-title":"Isatin-pyrazole benzenesulfonamide hybrids potently inhibit tumor-associated carbonic anhydrase isoforms IX and XII","volume":"103","author":"Ibrahim","year":"2015","journal-title":"Eur. J. Med. Chem."},{"issue":"4","key":"10.1016\/j.ejmech.2023.115180_bib43","doi-asserted-by":"crossref","first-page":"348","DOI":"10.4103\/0976-500X.103699","article-title":"Acetic acid induced painful endogenous infliction in writhing test on mice","volume":"3","author":"Gawade","year":"2012","journal-title":"J. Pharmacol. Pharmacother."},{"issue":"3","key":"10.1016\/j.ejmech.2023.115180_bib44","doi-asserted-by":"crossref","first-page":"544","DOI":"10.3181\/00379727-111-27849","article-title":"Carrageenin-induced edema in hind paw of the rat as an assay for antiinflammatory drugs","volume":"111","author":"Winter","year":"1962","journal-title":"Exp. Biol. Med."},{"key":"10.1016\/j.ejmech.2023.115180_bib45","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.201700093","article-title":"Synthesis of some novel 2,6-disubstituted pyridazin-3(2H)-one derivatives as analgesic, anti-inflammatory, and non-ulcerogenic agents","volume":"350","author":"Ibrahim","year":"2017","journal-title":"Arch. Pharm. Chem. Life Sci."},{"issue":"3","key":"10.1016\/j.ejmech.2023.115180_bib46","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.201900295","article-title":"Synthesis and biological screening of some novel 6\u2010substituted 2\u2010alkylpyridazin\u20103 (2H)\u2010ones as anti\u2010inflammatory and analgesic agents","volume":"353","author":"Loksha","year":"2020","journal-title":"Arch. Pharmazie"},{"key":"10.1016\/j.ejmech.2023.115180_bib47","doi-asserted-by":"crossref","unstructured":"Ahmed, Asmaa HH, Mamdouh FA Mohamed, Rasha M. Allam, Ayman Nafady, Shaaban K. Mohamed, Ahmed E. Gouda, and Eman AM Beshr. \"Design, synthesis, and molecular docking of novel pyrazole-chalcone analogs of lonazolac as 5-LOX, iNOS and tubulin polymerization inhibitors with potential anticancer and anti-inflammatory activities.\" Bioorg. Chem. 129 (2022): 106171.","DOI":"10.1016\/j.bioorg.2022.106171"},{"key":"10.1016\/j.ejmech.2023.115180_bib48","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1016\/S0021-9258(18)62326-9","article-title":"The carbon dioxide hydration activity of carbonic anhydrase: I. Stop-flow kinetic studies on the native human isoenzymes B and C","volume":"246","author":"Khalifah","year":"1971","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2023.115180_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112112","article-title":"Inclusion of a 5-fluorouracil moiety in nitrogenous bases derivatives as human carbonic anhydrase IX and XII inhibitors produced a targeted action against MDA-MB-231 and T47D breast cancer cells","volume":"190","author":"Petreni","year":"2020","journal-title":"Eur. J. Med. Chem."},{"issue":"6","key":"10.1016\/j.ejmech.2023.115180_bib50","doi-asserted-by":"crossref","first-page":"3317","DOI":"10.1021\/acs.jmedchem.9b02090","article-title":"Peat et al. \"Discovery of potent dual-tailed benzenesulfonamide inhibitors of human carbonic anhydrases implicated in glaucoma and in vivo profiling of their intraocular pressure-lowering action","volume":"63","author":"Fares","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115180_bib51a","doi-asserted-by":"crossref","unstructured":"Shaldam, Moataz, Wagdy M. Eldehna, Alessio Nocentini, Zainab M. Elsayed, Tamer M. Ibrahim, Rofaida Salem, Ramadan A. El-Domany, Clemente Capasso, Hatem A. Abdel-Aziz, and Claudiu T. Supuran. \"Development of novel benzofuran-based SLC-0111 analogs as selective cancer-associated carbonic anhydrase isoform IX inhibitors.\" Eur. J. Med. Chem. 216 (2021): 113283;.","DOI":"10.1016\/j.ejmech.2021.113283"},{"issue":"5","key":"10.1016\/j.ejmech.2023.115180_bib51b","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1021\/acsmedchemlett.0c00094","article-title":"Benzofuran-based carboxylic acids as carbonic anhydrase inhibitors and antiproliferative agents against breast cancer","volume":"11","author":"Eldehna","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"issue":"1","key":"10.1016\/j.ejmech.2023.115180_bib52","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1080\/14756366.2019.1652282","article-title":"Synthesis and biological evaluation of novel 3-(quinolin-4-ylamino) benzenesulfonamides as carbonic anhydrase isoforms I and II inhibitors","volume":"34","author":"Al-Sanea","year":"2019","journal-title":"J. Enzym. Inhib. Med. Chem."},{"issue":"7","key":"10.1016\/j.ejmech.2023.115180_bib53","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1016\/j.bmc.2017.02.037","article-title":"Synthesis of bulky-tailed sulfonamides incorporating pyrido [2, 3-d][1, 2, 4] triazolo [4, 3-a] pyrimidin-1 (5H)-yl) moieties and evaluation of their carbonic anhydrases I, II, IV and IX inhibitory effects","volume":"25","author":"Fares","year":"2017","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115180_bib54","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.3390\/ijms21072560","article-title":"Supuran. \"Benzylaminoethyureido-tailed benzenesulfonamides: design, synthesis, kinetic and X-ray investigations on human carbonic anhydrases","volume":"21","author":"Ali","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2023.115180_bib55","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1107\/S0907444910006554","article-title":"Atomic resolution studies of carbonic anhydrase II","volume":"66","author":"Behnke","year":"2010","journal-title":"Acta Crystallogr. D. Biol. Crystallogr."},{"key":"10.1016\/j.ejmech.2023.115180_bib56","doi-asserted-by":"crossref","first-page":"9004","DOI":"10.1021\/acs.jmedchem.5b01343","article-title":"Efficient expression and crystallization system of cancer-associated carbonic anhydrase isoform IX","volume":"58","author":"Leitans","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115180_bib57","doi-asserted-by":"crossref","first-page":"9545","DOI":"10.1073\/pnas.161301298","article-title":"Crystal structure of the dimeric extracellular domain of human carbonic anhydrase XII, a bitopic membrane protein overexpressed in certain cancer tumor cells","volume":"98","author":"Whittington","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"23","key":"10.1016\/j.ejmech.2023.115180_bib58","doi-asserted-by":"crossref","first-page":"7159","DOI":"10.1016\/j.bmcl.2010.07.054","article-title":"The novel benzopyran class of selective cyclooxygenase-2 inhibitors. Part 2: the second clinical candidate having a shorter and favorable human half-life","volume":"20","author":"Wang","year":"2010","journal-title":"Bioorg. Med. Chem. Lett"},{"issue":"7","key":"10.1016\/j.ejmech.2023.115180_bib59","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/s41589-020-0544-7","article-title":"Structural and mechanistic insights into 5-lipoxygenase inhibition by natural products","volume":"16","author":"Gilbert","year":"2020","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2023.115180_bib60","doi-asserted-by":"crossref","first-page":"D437","DOI":"10.1093\/nar\/gkaa1038","article-title":"RCSB Protein Data Bank: powerful new tools for exploring 3D structures of biological macromolecules for basic and applied research and education in fundamental biology, biomedicine, biotechnology, bioengineering and energy sciences","volume":"49","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejmech.2023.115180_sref58","series-title":"Schr\u00f6dinger Suite Release 2021-3","year":"2019"},{"key":"10.1016\/j.ejmech.2023.115180_bib61a","unstructured":"Maestro v.12.9;."},{"key":"10.1016\/j.ejmech.2023.115180_bib61b","unstructured":"Epik, v.5.7;."},{"key":"10.1016\/j.ejmech.2023.115180_bib61c","unstructured":"Macromodel v.13.3;."},{"key":"10.1016\/j.ejmech.2023.115180_bib61d","unstructured":"Glide, v.9.2;."},{"key":"10.1016\/j.ejmech.2023.115180_bib61e","unstructured":"Desmond, v.6.7;."},{"key":"10.1016\/j.ejmech.2023.115180_bib61f","unstructured":"Prime, v.5.5;."},{"key":"10.1016\/j.ejmech.2023.115180_bib61g","unstructured":"Impact, v.9.2;."},{"key":"10.1016\/j.ejmech.2023.115180_bib61h","unstructured":"Jaguar, v.11.3."},{"key":"10.1016\/j.ejmech.2023.115180_bib62","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1021\/acsmedchemlett.0c00403","article-title":"Benzoxaboroles: new potent inhibitors of the carbonic anhydrases of the pathogenic bacterium Vibrio cholerae","volume":"11","author":"Bonardi","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2023.115180_bib63","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1080\/14756366.2020.1752201","article-title":"The antibiotic furagin and its derivatives are isoform-selective human carbonic anhydrase inhibitors","volume":"35","author":"Pustenko","year":"2020","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115180_bib64","doi-asserted-by":"crossref","first-page":"4291","DOI":"10.1021\/acs.jctc.1c00302","article-title":"OPLS4: improving force field accuracy on challenging regimes of chemical space","volume":"17","author":"Lu","year":"2021","journal-title":"J. Chem. Theor. Comput."},{"key":"10.1016\/j.ejmech.2023.115180_bib65","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1002\/jcc.20084","article-title":"UCSF Chimera--a visualization system for exploratory research and analysis","volume":"25","author":"Pettersen","year":"2004","journal-title":"J. Comput. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523423000958?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523423000958?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:50:23Z","timestamp":1759330223000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523423000958"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":76,"alternative-id":["S0223523423000958"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2023.115180","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"4-(5-Amino-pyrazol-1-yl)benzenesulfonamide derivatives as novel multi-target anti-inflammatory agents endowed with inhibitory activity against COX-2, 5-LOX and carbonic anhydrase: Design, synthesis, and biological assessments","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2023.115180","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115180"}}